FOI #26-828 (11-13-26, 12:28 pm) - Subject - Public Records Request under your state's public records law [RR-1BV6-DCE2]
Name - Joe Meyerson
Affiliation -
Records Sought
For the period January 1, 2019 to the date of this request, I request the four items below. For item 1, please include any agreement that was in effect at any time in that period, whenever it was signed.
Vendor: Johnson & Johnson Health Care Systems Inc., which signs these agreements for the drug maker and may also appear as "Janssen Biotech," "Johnson & Johnson Innovative Medicine," or "J&J."
Products: Remicade and infliximab.
Please search the vendor name and the product names in your contract database, and also search the offices that keep these records outside it: Pharmacy, Purchasing, and Finance. These agreements are often signed for a whole health system, so please include agreements signed by your parent system or through your group purchasing organization. If no responsive record exists for an item, please state that in writing for that item.
1. Agreements
Executed agreements with the vendor, however titled, that set a price, discount, or rebate for Remicade or infliximab. Titles the vendor uses include "Agreement for REMICADE Products," "IDN Agreement," "GPO Agreement Supplement for REMICADE Products," "Portfolio Rebate Offering for Immunology and Medical Device," and "Contract Purchase Program." These agreements should be provided together with all schedules, exhibits, amendments, extensions, and termination notices, including any that also cover Simponi Aria, Stelara, or Tremfya.
2. Rebate and discount statements
Statements, reports, or letters from the vendor showing a rebate, "Performance Discount," or other payment or credit under the agreements in item 1, including any calculation of "Market Share" or "Infliximab Share," and any record showing how a payment was divided among your facilities.
3. Purchase history
Purchase reports showing the quantity purchased and the price paid, by calendar quarter, for Remicade (NDC 57894-0030-01), Janssen's unbranded infliximab (NDC 57894-0160-01), Inflectra, Renflexis, and Avsola. A report from your pharmacy wholesaler is sufficient.
4. Formulary decisions
Pharmacy and Therapeutics Committee agenda items, formulary reviews, and formulary decisions concerning Inflectra, Renflexis, Avsola, or any infliximab biosimilar, including any cost comparison with Remicade. For this item the period is January 1, 2016 to the date of this request.
If any pricing term is withheld as exempt, please release the remainder of the record with only that term redacted, and cite the exemption applied.
Please provide an estimate of any fees before processing this request and notify me before incurring costs. I agree to pay reasonable and customary fees for processing this request.
Please respond within the time required by law.
If you deny this request in whole or in part, please cite each specific exemption you believe justifies withholding and inform me of the applicable appeal procedures.
Thank you for your assistance.